speb/financial-data huggingface dataset:
DME.V income_statement (annual, 2023-09-30) — Operating Income: -6731812.00
DME.V income_statement (annual, 2023-09-30) — Operating Revenue: 1743622.00
DME.V balance_sheet (annual, 2023-09-30) — Ordinary Shares Number: 90258109.00
DME.V balance_sheet (annual, 2023-09-30) — Other Equity Adjustments: 1722702.00
DME.V balance_sheet (annual, 2023-09-30) — Other Equity Interest: 16330493.00
DME.V income_statement (annual, 2023-09-30) — Other Gand A: 1624273.00
DME.V income_statement (annual, 2023-09-30) — Other Income Expense: -5652434.00
DME.V cash_flow (annual, 2023-09-30) — Other Non Cash Items: -463273.00
DME.V income_statement (annual, 2023-09-30) — Other Operating Expenses: 1011207.00
DME.V balance_sheet (annual, 2023-09-30) — Other Properties: 50684382.00
DME.V balance_sheet (annual, 2023-09-30) — Other Short Term Investments: 0.00
DME.V balance_sheet (annual, 2023-09-30) — Payables: 956341.00
DME.V balance_sheet (annual, 2023-09-30) — Payables And Accrued Expenses: 956341.00
DME.V balance_sheet (annual, 2023-09-30) — Prepaid Assets: 635401.00
DME.V income_statement (annual, 2023-09-30) — Pretax Income: -11591723.00
DME.V cash_flow (annual, 2023-09-30) — Proceeds From Stock Option Exercised: 280920.00
DME.V cash_flow (annual, 2023-09-30) — Provisionand Write Offof Assets: 157212.00
DME.V cash_flow (annual, 2023-09-30) — Purchase Of Business: -3310000.00
DME.V cash_flow (annual, 2023-09-30) — Purchase Of Investment: -33800.00
DME.V balance_sheet (annual, 2023-09-30) — Receivables: 843405.00
DME.V income_statement (annual, 2023-09-30) — Reconciled Cost Of Revenue: 879116.00
DME.V income_statement (annual, 2023-09-30) — Reconciled Depreciation: 411639.00
DME.V balance_sheet (annual, 2023-09-30) — Retained Earnings: -48059976.00
DME.V income_statement (annual, 2023-09-30) — Salaries And Wages: 2497322.00
DME.V cash_flow (annual, 2023-09-30) — Sale Of Investment: 319690.00
DME.V cash_flow (annual, 2023-09-30) — Sale Of PPE: 8092.00
DME.V income_statement (annual, 2023-09-30) — Securities Amortization: 97469.00
DME.V income_statement (annual, 2023-09-30) — Selling And Marketing Expense: 745869.00
DME.V income_statement (annual, 2023-09-30) — Selling General And Administration: 5585563.00
DME.V balance_sheet (annual, 2023-09-30) — Share Issued: 90258109.00
DME.V income_statement (annual, 2023-09-30) — Special Income Charges: -5426273.00
DME.V cash_flow (annual, 2023-09-30) — Stock Based Compensation: 1830482.00
DME.V balance_sheet (annual, 2023-09-30) — Stockholders Equity: 50768595.00
DME.V balance_sheet (annual, 2023-09-30) — Tangible Book Value: 50768595.00
DME.V income_statement (annual, 2023-09-30) — Tax Effect Of Unusual Items: 0.00
DME.V income_statement (annual, 2023-09-30) — Tax Rate For Calcs: 0.00
DME.V balance_sheet (annual, 2023-09-30) — Total Assets: 59447424.00
DME.V balance_sheet (annual, 2023-09-30) — Total Capitalization: 50768595.00
DME.V balance_sheet (annual, 2023-09-30) — Total Equity Gross Minority Interest: 50768595.00
DME.V income_statement (annual, 2023-09-30) — Total Expenses: 8475434.00
DME.V balance_sheet (annual, 2023-09-30) — Total Liabilities Net Minority Interest: 8678829.00
DME.V balance_sheet (annual, 2023-09-30) — Total Non Current Assets: 45876736.00
DME.V balance_sheet (annual, 2023-09-30) — Total Non Current Liabilities Net Minority Interest: 7722488.00
DME.V income_statement (annual, 2023-09-30) — Total Unusual Items: -5652434.00
DME.V income_statement (annual, 2023-09-30) — Total Unusual Items Excluding Goodwill: -5652434.00
DME.V cash_flow (annual, 2023-09-30) — Unrealized Gain Loss On Investment Securities: -28315.00
DME.V balance_sheet (annual, 2023-09-30) — Working Capital: 12614347.00
DME.V income_statement (annual, 2023-09-30) — Write Off: 157212.00
DME.V income_statement (annual, 2024-09-30) — +Operating Expense: 4941585.00
DME.V income_statement (annual, 2024-09-30) — +Total Revenue: 860342.00
DME.V balance_sheet (annual, 2024-09-30) — Accounts Payable: 418956.00
DME.V balance_sheet (annual, 2024-09-30) — Accounts Receivable: 295306.00
DME.V balance_sheet (annual, 2024-09-30) — Accumulated Depreciation: -10744880.00
DME.V cash_flow (annual, 2024-09-30) — Asset Impairment Charge: 0.00
DME.V income_statement (annual, 2024-09-30) — Basic Average Shares: 90258109.00
DME.V income_statement (annual, 2024-09-30) — Basic EPS: -0.05
DME.V cash_flow (annual, 2024-09-30) — Beginning Cash Position: 12091882.00
DME.V cash_flow (annual, 2024-09-30) — Capital Expenditure: -7086513.00
DME.V cash_flow (annual, 2024-09-30) — Capital Expenditure Reported: -7086513.00
DME.V cash_flow (quarterly, 2024-09-30) — Capital Expenditure Reported: -477193.00
DME.V balance_sheet (annual, 2024-09-30) — Capital Stock: 80775376.00
DME.V balance_sheet (annual, 2024-09-30) — Cash And Cash Equivalents: 1183460.00
DME.V balance_sheet (annual, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 1183460.00
DME.V cash_flow (annual, 2024-09-30) — Cash Flow From Continuing Financing Activities: 0.00
DME.V cash_flow (annual, 2024-09-30) — Cash Flow From Continuing Investing Activities: -8284910.00
DME.V cash_flow (annual, 2024-09-30) — Cash Flow From Continuing Operating Activities: -2625618.00
DME.V cash_flow (annual, 2024-09-30) — Change In Account Payable: -287022.00
DME.V cash_flow (annual, 2024-09-30) — Change In Payable: -302086.00
DME.V cash_flow (annual, 2024-09-30) — Change In Payables And Accrued Expense: -302086.00
DME.V cash_flow (annual, 2024-09-30) — Change In Prepaid Assets: 548358.00
DME.V cash_flow (annual, 2024-09-30) — Change In Receivables: 650046.00
DME.V cash_flow (annual, 2024-09-30) — Change In Working Capital: 896318.00
DME.V cash_flow (annual, 2024-09-30) — Changes In Cash: -10910528.00
DME.V balance_sheet (annual, 2024-09-30) — Common Stock: 80775376.00
DME.V balance_sheet (annual, 2024-09-30) — Common Stock Equity: 47230623.00
DME.V cash_flow (annual, 2024-09-30) — Common Stock Issuance: 0.00
DME.V cash_flow (quarterly, 2024-09-30) — Common Stock Issuance: 0.00
DME.V income_statement (annual, 2024-09-30) — Cost Of Revenue: 1270008.00
DME.V balance_sheet (annual, 2024-09-30) — Current Assets: 1737918.00
DME.V balance_sheet (annual, 2024-09-30) — Current Liabilities: 441690.00
DME.V cash_flow (annual, 2024-09-30) — Depletion: 137734.00
DME.V income_statement (annual, 2024-09-30) — Depletion Income Statement: 0.00
DME.V income_statement (quarterly, 2024-09-30) — Depletion Income Statement: -181935.00
DME.V cash_flow (annual, 2024-09-30) — Depreciation: 130500.00
DME.V cash_flow (annual, 2024-09-30) — Depreciation Amortization Depletion: 268234.00
DME.V income_statement (annual, 2024-09-30) — Depreciation Amortization Depletion Income Statement: 130500.00
DME.V cash_flow (annual, 2024-09-30) — Depreciation And Amortization: 130500.00
DME.V income_statement (annual, 2024-09-30) — Depreciation And Amortization In Income Statement: 130500.00
DME.V income_statement (annual, 2024-09-30) — Depreciation Income Statement: 130500.00
DME.V income_statement (annual, 2024-09-30) — Diluted Average Shares: 90258109.00
DME.V income_statement (annual, 2024-09-30) — Diluted EPS: -0.05
DME.V income_statement (annual, 2024-09-30) — Diluted NI Availto Com Stockholders: -4580478.00
DME.V balance_sheet (annual, 2024-09-30) — Dueto Related Parties Current: 22734.00
DME.V balance_sheet (quarterly, 2024-09-30) — Dueto Related Parties Current: 22734.00
DME.V income_statement (annual, 2024-09-30) — EBIT: -5351251.00
DME.V income_statement (annual, 2024-09-30) — EBITDA: -5083017.00
DME.V cash_flow (annual, 2024-09-30) — Effect Of Exchange Rate Changes: 2106.00
DME.V cash_flow (annual, 2024-09-30) — End Cash Position: 1183460.00
DME.V cash_flow (annual, 2024-09-30) — Financing Cash Flow: 0.00
DME.V cash_flow (annual, 2024-09-30) — Free Cash Flow: -9712131.00
DME.V cash_flow (annual, 2024-09-30) — Gain Loss On Sale Of PPE: -186235.00
DME.V cash_flow (quarterly, 2024-09-30) — Gain Loss On Sale Of PPE: 173123.00
DME.V income_statement (annual, 2024-09-30) — Gain On Sale Of Ppe: 186235.00
DME.V income_statement (quarterly, 2024-09-30) — Gain On Sale Of Ppe: -173123.00
DME.V income_statement (annual, 2024-09-30) — Gain On Sale Of Security: -22678.00
DME.V balance_sheet (annual, 2024-09-30) — Gains Losses Not Affecting Retained Earnings: 1613431.00
DME.V income_statement (annual, 2024-09-30) — General And Administrative Expense: 3696132.00
DME.V balance_sheet (annual, 2024-09-30) — Gross PPE: 57374070.00
DME.V income_statement (annual, 2024-09-30) — Gross Profit: -409666.00
DME.V balance_sheet (annual, 2024-09-30) — Held To Maturity Securities: 156772.00
DME.V income_statement (annual, 2024-09-30) — Impairment Of Capital Assets: 0.00
DME.V income_statement (annual, 2024-09-30) — Insurance And Claims: 532038.00
DME.V income_statement (quarterly, 2024-09-30) — Insurance And Claims: 53916.00
DME.V income_statement (annual, 2024-09-30) — Interest Income: 503746.00
DME.V income_statement (annual, 2024-09-30) — Interest Income Non Operating: 503746.00
DME.V balance_sheet (annual, 2024-09-30) — Invested Capital: 47230623.00
DME.V cash_flow (annual, 2024-09-30) — Investing Cash Flow: -8284910.00
DME.V balance_sheet (annual, 2024-09-30) — Investmentin Financial Assets: 156772.00
DME.V balance_sheet (annual, 2024-09-30) — Investments And Advances: 156772.00
DME.V cash_flow (annual, 2024-09-30) — Issuance Of Capital Stock: 0.00
DME.V cash_flow (quarterly, 2024-09-30) — Issuance Of Capital Stock: 0.00
DME.V balance_sheet (annual, 2024-09-30) — Land And Improvements: 271622.00
DME.V balance_sheet (annual, 2024-09-30) — Long Term Provisions: 2854977.00
DME.V balance_sheet (annual, 2024-09-30) — Machinery Furniture Equipment: 23973764.00
DME.V balance_sheet (quarterly, 2024-09-30) — Machinery Furniture Equipment: 23973764.00
DME.V cash_flow (annual, 2024-09-30) — Net Business Purchase And Sale: 0.00
DME.V cash_flow (annual, 2024-09-30) — Net Common Stock Issuance: 0.00
DME.V cash_flow (quarterly, 2024-09-30) — Net Common Stock Issuance: 0.00
DME.V cash_flow (annual, 2024-09-30) — Net Foreign Currency Exchange Gain Loss: 20320.00
DME.V income_statement (annual, 2024-09-30) — Net Income: -4580478.00
DME.V income_statement (annual, 2024-09-30) — Net Income Common Stockholders: -4580478.00
DME.V income_statement (annual, 2024-09-30) — Net Income Continuous Operations: -4580478.00
DME.V income_statement (annual, 2024-09-30) — Net Income From Continuing And Discontinued Operation: -4580478.00
DME.V income_statement (annual, 2024-09-30) — Net Income From Continuing Operation Net Minority Interest: -4580478.00
DME.V cash_flow (annual, 2024-09-30) — Net Income From Continuing Operations: -4580478.00
DME.V income_statement (annual, 2024-09-30) — Net Income Including Noncontrolling Interests: -4580478.00
DME.V income_statement (annual, 2024-09-30) — Net Interest Income: 503746.00
DME.V cash_flow (annual, 2024-09-30) — Net Investment Purchase And Sale: -55350.00
DME.V cash_flow (quarterly, 2024-09-30) — Net Investment Purchase And Sale: -55350.00
DME.V income_statement (annual, 2024-09-30) — Net Non Operating Interest Income Expense: 503746.00
DME.V cash_flow (annual, 2024-09-30) — Net Other Investing Changes: -1198397.00
DME.V balance_sheet (annual, 2024-09-30) — Net PPE: 46629190.00
DME.V cash_flow (annual, 2024-09-30) — Net PPE Purchase And Sale: 0.00
DME.V balance_sheet (annual, 2024-09-30) — Net Tangible Assets: 47230623.00
DME.V balance_sheet (annual, 2024-09-30) — Non Current Accounts Receivable: 734938.00
DME.V balance_sheet (annual, 2024-09-30) — Non Current Note Receivables: 484860.00
DME.V balance_sheet (quarterly, 2024-09-30) — Non Current Note Receivables: 484860.00
DME.V income_statement (annual, 2024-09-30) — Normalized EBITDA: -5350044.00
DME.V income_statement (annual, 2024-09-30) — Normalized Income: -4847505.00
DME.V cash_flow (annual, 2024-09-30) — Operating Cash Flow: -2625618.00
DME.V cash_flow (annual, 2024-09-30) — Operating Gains Losses: -165915.00
DME.V income_statement (annual, 2024-09-30) — Operating Income: -5351251.00
DME.V income_statement (annual, 2024-09-30) — Operating Revenue: 860342.00
DME.V balance_sheet (annual, 2024-09-30) — Ordinary Shares Number: 90258109.00
DME.V balance_sheet (annual, 2024-09-30) — Other Equity Adjustments: 1613431.00
DME.V balance_sheet (annual, 2024-09-30) — Other Equity Interest: 17482270.00
DME.V income_statement (annual, 2024-09-30) — Other Gand A: 1907538.00
DME.V income_statement (annual, 2024-09-30) — Other Income Expense: 267027.00
DME.V cash_flow (annual, 2024-09-30) — Other Non Cash Items: 51032.00
DME.V balance_sheet (annual, 2024-09-30) — Other Non Current Assets: 783612.00
DME.V income_statement (annual, 2024-09-30) — Other Operating Expenses: 660376.00
DME.V balance_sheet (annual, 2024-09-30) — Other Properties: 57102448.00
DME.V balance_sheet (annual, 2024-09-30) — Other Receivables: 172109.00
DME.V balance_sheet (annual, 2024-09-30) — Payables: 441690.00
DME.V balance_sheet (annual, 2024-09-30) — Payables And Accrued Expenses: 441690.00
DME.V balance_sheet (annual, 2024-09-30) — Prepaid Assets: 87043.00
DME.V income_statement (annual, 2024-09-30) — Pretax Income: -4580478.00
DME.V cash_flow (annual, 2024-09-30) — Proceeds From Stock Option Exercised: 0.00
DME.V cash_flow (quarterly, 2024-09-30) — Proceeds From Stock Option Exercised: 0.00
DME.V cash_flow (annual, 2024-09-30) — Provisionand Write Offof Assets: -103470.00
DME.V cash_flow (annual, 2024-09-30) — Purchase Of Business: 0.00
DME.V cash_flow (annual, 2024-09-30) — Purchase Of Investment: -55350.00
DME.V balance_sheet (annual, 2024-09-30) — Receivables: 467415.00
DME.V income_statement (annual, 2024-09-30) — Reconciled Cost Of Revenue: 1132274.00
DME.V income_statement (annual, 2024-09-30) — Reconciled Depreciation: 268234.00
DME.V income_statement (annual, 2024-09-30) — Restructuring And Mergern Acquisition: 0.00
DME.V balance_sheet (annual, 2024-09-30) — Retained Earnings: -52640454.00
DME.V income_statement (annual, 2024-09-30) — Salaries And Wages: 1256556.00
DME.V cash_flow (annual, 2024-09-30) — Sale Of Investment: 0.00
DME.V cash_flow (quarterly, 2024-09-30) — Sale Of Investment: 0.00
DME.V cash_flow (annual, 2024-09-30) — Sale Of PPE: 0.00
DME.V income_statement (annual, 2024-09-30) — Selling And Marketing Expense: 134871.00
DME.V income_statement (annual, 2024-09-30) — Selling General And Administration: 3831003.00
DME.V balance_sheet (annual, 2024-09-30) — Share Issued: 90258109.00
DME.V income_statement (annual, 2024-09-30) — Special Income Charges: 289705.00
DME.V cash_flow (annual, 2024-09-30) — Stock Based Compensation: 1008661.00
DME.V cash_flow (quarterly, 2024-09-30) — Stock Based Compensation: 27264.00
DME.V balance_sheet (annual, 2024-09-30) — Stockholders Equity: 47230623.00
DME.V balance_sheet (annual, 2024-09-30) — Tangible Book Value: 47230623.00
DME.V income_statement (annual, 2024-09-30) — Tax Effect Of Unusual Items: 0.00
DME.V income_statement (annual, 2024-09-30) — Tax Rate For Calcs: 0.00
DME.V balance_sheet (annual, 2024-09-30) — Total Assets: 50527290.00
DME.V balance_sheet (annual, 2024-09-30) — Total Capitalization: 47230623.00
DME.V balance_sheet (annual, 2024-09-30) — Total Equity Gross Minority Interest: 47230623.00
DME.V income_statement (annual, 2024-09-30) — Total Expenses: 6211593.00
DME.V balance_sheet (annual, 2024-09-30) — Total Liabilities Net Minority Interest: 3296667.00
DME.V balance_sheet (annual, 2024-09-30) — Total Non Current Assets: 48789372.00
DME.V balance_sheet (annual, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 2854977.00
DME.V income_statement (annual, 2024-09-30) — Total Unusual Items: 267027.00
DME.V income_statement (annual, 2024-09-30) — Total Unusual Items Excluding Goodwill: 267027.00
DME.V cash_flow (annual, 2024-09-30) — Unrealized Gain Loss On Investment Securities: 0.00
DME.V cash_flow (quarterly, 2024-09-30) — Unrealized Gain Loss On Investment Securities: 0.00
DME.V balance_sheet (annual, 2024-09-30) — Working Capital: 1296228.00
DME.V income_statement (annual, 2024-09-30) — Write Off: -103470.00
DME.V income_statement (quarterly, 2024-12-31) — +Operating Expense: 657914.00
DME.V income_statement (quarterly, 2024-12-31) — +Total Revenue: 132964.00
DME.V balance_sheet (quarterly, 2024-12-31) — Accounts Payable: 226049.00
DME.V balance_sheet (quarterly, 2024-12-31) — Accounts Receivable: 191558.00
DME.V balance_sheet (quarterly, 2024-12-31) — Accumulated Depreciation: -10777578.00
DME.V income_statement (quarterly, 2024-12-31) — Basic Average Shares: 90258109.00
DME.V income_statement (quarterly, 2024-12-31) — Basic EPS: -0.01
DME.V cash_flow (quarterly, 2024-12-31) — Beginning Cash Position: 1183460.00
DME.V cash_flow (quarterly, 2024-12-31) — Capital Expenditure: -215081.00
DME.V cash_flow (quarterly, 2024-12-31) — Capital Expenditure Reported: -215081.00
DME.V balance_sheet (quarterly, 2024-12-31) — Capital Stock: 80775376.00
DME.V balance_sheet (quarterly, 2024-12-31) — Cash And Cash Equivalents: 546209.00
DME.V balance_sheet (quarterly, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 546209.00
DME.V cash_flow (quarterly, 2024-12-31) — Cash Flow From Continuing Financing Activities: 0.00
DME.V cash_flow (quarterly, 2024-12-31) — Cash Flow From Continuing Investing Activities: -53595.00
DME.V cash_flow (quarterly, 2024-12-31) — Cash Flow From Continuing Operating Activities: -581870.00
DME.V cash_flow (quarterly, 2024-12-31) — Change In Account Payable: -17115.00
DME.V cash_flow (quarterly, 2024-12-31) — Change In Payable: -39849.00
DME.V cash_flow (quarterly, 2024-12-31) — Change In Payables And Accrued Expense: -39849.00
DME.V cash_flow (quarterly, 2024-12-31) — Change In Prepaid Assets: 5388.00
DME.V cash_flow (quarterly, 2024-12-31) — Change In Receivables: 103748.00
DME.V cash_flow (quarterly, 2024-12-31) — Change In Working Capital: 69287.00
DME.V cash_flow (quarterly, 2024-12-31) — Changes In Cash: -635465.00
DME.V balance_sheet (quarterly, 2024-12-31) — Common Stock: 80775376.00
DME.V balance_sheet (quarterly, 2024-12-31) — Common Stock Equity: 49254853.00
DME.V income_statement (quarterly, 2024-12-31) — Cost Of Revenue: 218679.00
DME.V balance_sheet (quarterly, 2024-12-31) — Current Assets: 950382.00
DME.V balance_sheet (quarterly, 2024-12-31) — Current Liabilities: 226049.00
DME.V cash_flow (quarterly, 2024-12-31) — Depletion: 3299.00
DME.V income_statement (quarterly, 2024-12-31) — Depletion Income Statement: 0.00
DME.V cash_flow (quarterly, 2024-12-31) — Depreciation: 12103.00
DME.V cash_flow (quarterly, 2024-12-31) — Depreciation Amortization Depletion: 15402.00
DME.V income_statement (quarterly, 2024-12-31) — Depreciation Amortization Depletion Income Statement: 12103.00
DME.V cash_flow (quarterly, 2024-12-31) — Depreciation And Amortization: 12103.00
DME.V income_statement (quarterly, 2024-12-31) — Depreciation And Amortization In Income Statement: 12103.00
DME.V income_statement (quarterly, 2024-12-31) — Depreciation Income Statement: 12103.00
DME.V income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 90258109.00
DME.V income_statement (quarterly, 2024-12-31) — Diluted EPS: -0.01
DME.V income_statement (quarterly, 2024-12-31) — Diluted NI Availto Com Stockholders: -647262.00
DME.V balance_sheet (quarterly, 2024-12-31) — Dueto Related Parties Current: 0.00
DME.V income_statement (quarterly, 2024-12-31) — EBIT: -743629.00
DME.V income_statement (quarterly, 2024-12-31) — EBITDA: -728227.00
DME.V cash_flow (quarterly, 2024-12-31) — Effect Of Exchange Rate Changes: -1786.00
DME.V cash_flow (quarterly, 2024-12-31) — End Cash Position: 546209.00
DME.V cash_flow (quarterly, 2024-12-31) — Financing Cash Flow: 0.00
DME.V cash_flow (quarterly, 2024-12-31) — Free Cash Flow: -796951.00
DME.V income_statement (quarterly, 2024-12-31) — Gain On Sale Of Security: -1786.00
DME.V balance_sheet (quarterly, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: 4284923.00
DME.V income_statement (quarterly, 2024-12-31) — General And Administrative Expense: 379470.00
DME.V balance_sheet (quarterly, 2024-12-31) — Gross PPE: 60309405.00
DME.V income_statement (quarterly, 2024-12-31) — Gross Profit: -85715.00
DME.V balance_sheet (quarterly, 2024-12-31) — Held To Maturity Securities: 166707.00
DME.V income_statement (quarterly, 2024-12-31) — Interest Income: 85209.00
DME.V income_statement (quarterly, 2024-12-31) — Interest Income Non Operating: 85209.00
DME.V balance_sheet (quarterly, 2024-12-31) — Invested Capital: 49254853.00
DME.V cash_flow (quarterly, 2024-12-31) — Investing Cash Flow: -53595.00
DME.V balance_sheet (quarterly, 2024-12-31) — Investmentin Financial Assets: 166707.00
DME.V balance_sheet (quarterly, 2024-12-31) — Investments And Advances: 166707.00
DME.V balance_sheet (quarterly, 2024-12-31) — Land And Improvements: 288836.00
DME.V balance_sheet (quarterly, 2024-12-31) — Long Term Provisions: 3065358.00
DME.V balance_sheet (quarterly, 2024-12-31) — Machinery Furniture Equipment: 25550436.00
DME.V cash_flow (quarterly, 2024-12-31) — Net Foreign Currency Exchange Gain Loss: 1786.00
DME.V income_statement (quarterly, 2024-12-31) — Net Income: -647262.00
DME.V income_statement (quarterly, 2024-12-31) — Net Income Common Stockholders: -647262.00
DME.V income_statement (quarterly, 2024-12-31) — Net Income Continuous Operations: -647262.00
DME.V income_statement (quarterly, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -647262.00
DME.V income_statement (quarterly, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -647262.00
DME.V cash_flow (quarterly, 2024-12-31) — Net Income From Continuing Operations: -647262.00
DME.V income_statement (quarterly, 2024-12-31) — Net Income Including Noncontrolling Interests: -647262.00
DME.V income_statement (quarterly, 2024-12-31) — Net Interest Income: 85209.00
DME.V income_statement (quarterly, 2024-12-31) — Net Non Operating Interest Income Expense: 85209.00
DME.V cash_flow (quarterly, 2024-12-31) — Net Other Investing Changes: 161486.00
DME.V balance_sheet (quarterly, 2024-12-31) — Net PPE: 49531827.00
DME.V balance_sheet (quarterly, 2024-12-31) — Net Tangible Assets: 49254853.00
DME.V balance_sheet (quarterly, 2024-12-31) — Non Current Accounts Receivable: 789705.00
DME.V balance_sheet (quarterly, 2024-12-31) — Non Current Note Receivables: 324027.00
DME.V income_statement (quarterly, 2024-12-31) — Normalized EBITDA: -739385.00
DME.V income_statement (quarterly, 2024-12-31) — Normalized Income: -658420.00
DME.V cash_flow (quarterly, 2024-12-31) — Operating Cash Flow: -581870.00
DME.V cash_flow (quarterly, 2024-12-31) — Operating Gains Losses: 1786.00
DME.V income_statement (quarterly, 2024-12-31) — Operating Income: -743629.00
DME.V income_statement (quarterly, 2024-12-31) — Operating Revenue: 132964.00
DME.V balance_sheet (quarterly, 2024-12-31) — Ordinary Shares Number: 90258109.00
DME.V balance_sheet (quarterly, 2024-12-31) — Other Equity Adjustments: 4284923.00
DME.V balance_sheet (quarterly, 2024-12-31) — Other Equity Interest: 17482270.00
DME.V income_statement (quarterly, 2024-12-31) — Other Gand A: 363095.00
DME.V income_statement (quarterly, 2024-12-31) — Other Income Expense: 11158.00
DME.V cash_flow (quarterly, 2024-12-31) — Other Non Cash Items: -21083.00
DME.V balance_sheet (quarterly, 2024-12-31) — Other Non Current Assets: 783612.00
DME.V income_statement (quarterly, 2024-12-31) — Other Operating Expenses: 109818.00
DME.V balance_sheet (quarterly, 2024-12-31) — Other Properties: 60020569.00
DME.V balance_sheet (quarterly, 2024-12-31) — Other Receivables: 130960.00
DME.V income_statement (quarterly, 2024-12-31) — Other Special Charges: -12944.00
DME.V balance_sheet (quarterly, 2024-12-31) — Payables: 226049.00
DME.V balance_sheet (quarterly, 2024-12-31) — Payables And Accrued Expenses: 226049.00
DME.V balance_sheet (quarterly, 2024-12-31) — Prepaid Assets: 81655.00
DME.V income_statement (quarterly, 2024-12-31) — Pretax Income: -647262.00
DME.V cash_flow (quarterly, 2024-12-31) — Proceeds From Stock Option Exercised: 0.00
DME.V balance_sheet (quarterly, 2024-12-31) — Receivables: 322518.00
DME.V income_statement (quarterly, 2024-12-31) — Reconciled Cost Of Revenue: 215380.00
DME.V income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 15402.00
DME.V income_statement (quarterly, 2024-12-31) — Restructuring And Mergern Acquisition: 0.00
DME.V balance_sheet (quarterly, 2024-12-31) — Retained Earnings: -53287716.00
DME.V income_statement (quarterly, 2024-12-31) — Salaries And Wages: 16375.00
DME.V income_statement (quarterly, 2024-12-31) — Selling And Marketing Expense: 17049.00
DME.V income_statement (quarterly, 2024-12-31) — Selling General And Administration: 396519.00
DME.V balance_sheet (quarterly, 2024-12-31) — Share Issued: 90258109.00
DME.V income_statement (quarterly, 2024-12-31) — Special Income Charges: 12944.00
DME.V cash_flow (quarterly, 2024-12-31) — Stock Based Compensation: 0.00
DME.V balance_sheet (quarterly, 2024-12-31) — Stockholders Equity: 49254853.00
DME.V balance_sheet (quarterly, 2024-12-31) — Tangible Book Value: 49254853.00
DME.V income_statement (quarterly, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
DME.V income_statement (quarterly, 2024-12-31) — Tax Rate For Calcs: 0.00
DME.V balance_sheet (quarterly, 2024-12-31) — Total Assets: 52546260.00
DME.V balance_sheet (quarterly, 2024-12-31) — Total Capitalization: 49254853.00
DME.V balance_sheet (quarterly, 2024-12-31) — Total Equity Gross Minority Interest: 49254853.00
DME.V income_statement (quarterly, 2024-12-31) — Total Expenses: 876593.00
DME.V balance_sheet (quarterly, 2024-12-31) — Total Liabilities Net Minority Interest: 3291407.00
DME.V balance_sheet (quarterly, 2024-12-31) — Total Non Current Assets: 51595878.00
DME.V balance_sheet (quarterly, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 3065358.00
DME.V income_statement (quarterly, 2024-12-31) — Total Unusual Items: 11158.00
DME.V income_statement (quarterly, 2024-12-31) — Total Unusual Items Excluding Goodwill: 11158.00
DME.V balance_sheet (quarterly, 2024-12-31) — Working Capital: 724333.00
DME.V income_statement (quarterly, 2025-03-31) — +Operating Expense: 716115.00
DME.V income_statement (quarterly, 2025-03-31) — +Total Revenue: 149313.00
DME.V balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 353029.00
DME.V balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 165643.00
DME.V balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -10789440.00
DME.V income_statement (quarterly, 2025-03-31) — Basic Average Shares: 90694219.00
DME.V income_statement (quarterly, 2025-03-31) — Basic EPS: -0.01
DME.V cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 546209.00
DME.V cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -212741.00
DME.V cash_flow (quarterly, 2025-03-31) — Capital Expenditure Reported: -212741.00
DME.V balance_sheet (quarterly, 2025-03-31) — Capital Stock: 81459968.00
DME.V balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 396502.00
DME.V balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 396502.00
DME.V cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: 699380.00
DME.V cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: -208879.00
DME.V cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: -640466.00
DME.V cash_flow (quarterly, 2025-03-31) — Change In Account Payable: 25819.00
DME.V cash_flow (quarterly, 2025-03-31) — Change In Payable: 25819.00
DME.V cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: 25819.00
DME.V cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: -26641.00
DME.V cash_flow (quarterly, 2025-03-31) — Change In Receivables: 25915.00
DME.V cash_flow (quarterly, 2025-03-31) — Change In Working Capital: 25093.00
DME.V cash_flow (quarterly, 2025-03-31) — Changes In Cash: -149965.00
DME.V balance_sheet (quarterly, 2025-03-31) — Common Stock: 81459968.00
DME.V balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 49241577.00
DME.V income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 176316.00
DME.V balance_sheet (quarterly, 2025-03-31) — Current Assets: 801401.00
DME.V balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 353029.00
DME.V cash_flow (quarterly, 2025-03-31) — Depletion: 518.00
DME.V income_statement (quarterly, 2025-03-31) — Depletion Income Statement: 0.00
DME.V cash_flow (quarterly, 2025-03-31) — Depreciation: 12414.00
DME.V cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 12932.00
DME.V income_statement (quarterly, 2025-03-31) — Depreciation Amortization Depletion Income Statement: 12414.00
DME.V cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 12414.00
DME.V income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 12414.00
DME.V income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 12414.00
DME.V income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 90694219.00
DME.V income_statement (quarterly, 2025-03-31) — Diluted EPS: -0.01
DME.V income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -653746.00
DME.V balance_sheet (quarterly, 2025-03-31) — Dueto Related Parties Current: 0.00
DME.V income_statement (quarterly, 2025-03-31) — EBIT: -743118.00
DME.V income_statement (quarterly, 2025-03-31) — EBITDA: -730186.00
DME.V cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: 258.00
DME.V cash_flow (quarterly, 2025-03-31) — End Cash Position: 396502.00
DME.V cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: 699380.00
DME.V cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -853207.00
DME.V income_statement (quarterly, 2025-03-31) — Gain On Sale Of Ppe: 0.00
DME.V income_statement (quarterly, 2025-03-31) — Gain On Sale Of Security: 364.00
DME.V balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: 4226013.00
DME.V income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 379220.00
DME.V balance_sheet (quarterly, 2025-03-31) — Gross PPE: 60549616.00
DME.V income_statement (quarterly, 2025-03-31) — Gross Profit: -27003.00
DME.V balance_sheet (quarterly, 2025-03-31) — Held To Maturity Securities: 166497.00
DME.V income_statement (quarterly, 2025-03-31) — Insurance And Claims: 91920.00
DME.V income_statement (quarterly, 2025-03-31) — Interest Income: 89008.00
DME.V income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 89008.00
DME.V balance_sheet (quarterly, 2025-03-31) — Invested Capital: 49241577.00
DME.V cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: -208879.00
DME.V balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 166497.00
DME.V balance_sheet (quarterly, 2025-03-31) — Investments And Advances: 166497.00
DME.V balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 288472.00
DME.V balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 3096400.00
DME.V cash_flow (quarterly, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: -364.00
DME.V income_statement (quarterly, 2025-03-31) — Net Income: -653746.00
DME.V income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -653746.00
DME.V income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -653746.00
DME.V income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -653746.00
DME.V income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -653746.00
DME.V cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -653746.00
DME.V income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -653746.00
DME.V income_statement (quarterly, 2025-03-31) — Net Interest Income: 89008.00
DME.V income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: 89008.00
DME.V cash_flow (quarterly, 2025-03-31) — Net Other Investing Changes: 3862.00
DME.V balance_sheet (quarterly, 2025-03-31) — Net PPE: 49760176.00
DME.V balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 49241577.00
DME.V balance_sheet (quarterly, 2025-03-31) — Non Current Accounts Receivable: 743468.00
DME.V balance_sheet (quarterly, 2025-03-31) — Non Current Note Receivables: 382935.00
DME.V income_statement (quarterly, 2025-03-31) — Normalized EBITDA: -730550.00
DME.V income_statement (quarterly, 2025-03-31) — Normalized Income: -654110.00
DME.V cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: -640466.00
DME.V cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: -364.00
DME.V income_statement (quarterly, 2025-03-31) — Operating Income: -743118.00
DME.V income_statement (quarterly, 2025-03-31) — Operating Revenue: 149313.00
DME.V balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 93284109.00
DME.V balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: 4226013.00
DME.V balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 17497058.00
DME.V income_statement (quarterly, 2025-03-31) — Other Gand A: 270497.00
DME.V income_statement (quarterly, 2025-03-31) — Other Income Expense: 364.00
DME.V cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: -24381.00
DME.V balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 836529.00
DME.V income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 75830.00
DME.V balance_sheet (quarterly, 2025-03-31) — Other Properties: 60261144.00
DME.V balance_sheet (quarterly, 2025-03-31) — Other Receivables: 130960.00
DME.V balance_sheet (quarterly, 2025-03-31) — Payables: 353029.00
DME.V balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 353029.00
DME.V balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 108296.00
DME.V income_statement (quarterly, 2025-03-31) — Pretax Income: -653746.00
DME.V cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: 0.00
DME.V balance_sheet (quarterly, 2025-03-31) — Receivables: 296603.00
DME.V income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 175798.00
DME.V income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 12932.00
DME.V income_statement (quarterly, 2025-03-31) — Restructuring And Mergern Acquisition: 0.00
DME.V balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -53941462.00
DME.V income_statement (quarterly, 2025-03-31) — Salaries And Wages: 16803.00
DME.V income_statement (quarterly, 2025-03-31) — Selling And Marketing Expense: 46831.00
DME.V income_statement (quarterly, 2025-03-31) — Selling General And Administration: 426051.00
DME.V balance_sheet (quarterly, 2025-03-31) — Share Issued: 93284109.00
DME.V income_statement (quarterly, 2025-03-31) — Special Income Charges: 0.00
DME.V cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 0.00
DME.V balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 49241577.00
DME.V balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 49241577.00
DME.V income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
DME.V income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.00
DME.V balance_sheet (quarterly, 2025-03-31) — Total Assets: 52691006.00
DME.V balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 49241577.00
DME.V balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 49241577.00
DME.V income_statement (quarterly, 2025-03-31) — Total Expenses: 892431.00
DME.V balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 3449429.00
DME.V balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 51889605.00
DME.V balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 3096400.00
DME.V income_statement (quarterly, 2025-03-31) — Total Unusual Items: 364.00
DME.V income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 364.00
DME.V balance_sheet (quarterly, 2025-03-31) — Working Capital: 448372.00
DME.V income_statement (quarterly, 2025-06-30) — +Operating Expense: 531615.00
DME.V income_statement (quarterly, 2025-06-30) — +Total Revenue: 79691.00
DME.V balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 322840.00
DME.V balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 56502.00
DME.V balance_sheet (quarterly, 2025-06-30) — Accumulated Depreciation: -10783299.00
DME.V income_statement (quarterly, 2025-06-30) — Basic Average Shares: 93861471.00
DME.V income_statement (quarterly, 2025-06-30) — Basic EPS: 0.00
DME.V cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 396502.00
DME.V cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -60209.00
DME.V cash_flow (quarterly, 2025-06-30) — Capital Expenditure Reported: -60209.00
DME.V balance_sheet (quarterly, 2025-06-30) — Capital Stock: 81659399.00
DME.V balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 376410.00
DME.V balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 376410.00
DME.V cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: 204160.00
DME.V cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: 230329.00
DME.V cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: -352789.00
DME.V cash_flow (quarterly, 2025-06-30) — Change In Account Payable: -30189.00
DME.V cash_flow (quarterly, 2025-06-30) — Change In Payable: -30189.00
DME.V cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: -30189.00
DME.V cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: 27674.00
DME.V cash_flow (quarterly, 2025-06-30) — Change In Receivables: 109141.00
DME.V cash_flow (quarterly, 2025-06-30) — Change In Working Capital: 106626.00
DME.V cash_flow (quarterly, 2025-06-30) — Changes In Cash: 81700.00
DME.V balance_sheet (quarterly, 2025-06-30) — Common Stock: 81659399.00
DME.V balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 46758212.00
DME.V cash_flow (quarterly, 2025-06-30) — Common Stock Issuance: 204160.00
DME.V income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 87976.00
DME.V balance_sheet (quarterly, 2025-06-30) — Current Assets: 644494.00
DME.V balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 322840.00
DME.V cash_flow (quarterly, 2025-06-30) — Depletion: -30.00
DME.V income_statement (quarterly, 2025-06-30) — Depletion Income Statement: 0.00
DME.V cash_flow (quarterly, 2025-06-30) — Depreciation: 11966.00
DME.V cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 11936.00
DME.V income_statement (quarterly, 2025-06-30) — Depreciation Amortization Depletion Income Statement: 11966.00
DME.V cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 11966.00
DME.V income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 11966.00
DME.V income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 11966.00
DME.V income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 93861471.00
DME.V income_statement (quarterly, 2025-06-30) — Diluted EPS: 0.00
DME.V income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: -453168.00
DME.V balance_sheet (quarterly, 2025-06-30) — Dueto Related Parties Current: 0.00
DME.V income_statement (quarterly, 2025-06-30) — EBIT: -539900.00
DME.V income_statement (quarterly, 2025-06-30) — EBITDA: -527934.00
DME.V cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: -101792.00
DME.V cash_flow (quarterly, 2025-06-30) — End Cash Position: 376410.00
DME.V cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: 204160.00
DME.V cash_flow (quarterly, 2025-06-30) — Free Cash Flow: -412998.00
DME.V cash_flow (quarterly, 2025-06-30) — Gain Loss On Sale Of PPE: 0.00
DME.V income_statement (quarterly, 2025-06-30) — Gain On Sale Of Ppe: 0.00
DME.V income_statement (quarterly, 2025-06-30) — Gain On Sale Of Security: -742.00
DME.V balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: 1991656.00
DME.V income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 290987.00
DME.V balance_sheet (quarterly, 2025-06-30) — Gross PPE: 58390495.00
DME.V income_statement (quarterly, 2025-06-30) — Gross Profit: -8285.00
DME.V balance_sheet (quarterly, 2025-06-30) — Held To Maturity Securities: 158363.00
DME.V income_statement (quarterly, 2025-06-30) — Insurance And Claims: 69890.00
DME.V income_statement (quarterly, 2025-06-30) — Interest Income: 87474.00
DME.V income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 87474.00
DME.V balance_sheet (quarterly, 2025-06-30) — Invested Capital: 46758212.00
DME.V cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: 230329.00
DME.V balance_sheet (quarterly, 2025-06-30) — Investmentin Financial Assets: 158363.00
DME.V balance_sheet (quarterly, 2025-06-30) — Investments And Advances: 158363.00
DME.V cash_flow (quarterly, 2025-06-30) — Issuance Of Capital Stock: 204160.00
DME.V balance_sheet (quarterly, 2025-06-30) — Land And Improvements: 274379.00
DME.V balance_sheet (quarterly, 2025-06-30) — Long Term Provisions: 2979483.00
DME.V cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: 204160.00
DME.V cash_flow (quarterly, 2025-06-30) — Net Foreign Currency Exchange Gain Loss: 742.00
DME.V income_statement (quarterly, 2025-06-30) — Net Income: -453168.00
DME.V income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: -453168.00
DME.V income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: -453168.00
DME.V income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: -453168.00
DME.V income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: -453168.00
DME.V cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: -453168.00
DME.V income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -453168.00
DME.V income_statement (quarterly, 2025-06-30) — Net Interest Income: 87474.00
DME.V income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: 87474.00
DME.V cash_flow (quarterly, 2025-06-30) — Net Other Investing Changes: 290538.00
DME.V balance_sheet (quarterly, 2025-06-30) — Net PPE: 47607196.00
DME.V balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 46758212.00
DME.V balance_sheet (quarterly, 2025-06-30) — Non Current Accounts Receivable: 656658.00
DME.V balance_sheet (quarterly, 2025-06-30) — Non Current Note Receivables: 194030.00
DME.V income_statement (quarterly, 2025-06-30) — Normalized EBITDA: -527192.00
DME.V income_statement (quarterly, 2025-06-30) — Normalized Income: -452426.00
DME.V cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: -352789.00
DME.V cash_flow (quarterly, 2025-06-30) — Operating Gains Losses: 742.00
DME.V income_statement (quarterly, 2025-06-30) — Operating Income: -539900.00
DME.V income_statement (quarterly, 2025-06-30) — Operating Revenue: 79691.00
DME.V balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 94184109.00
DME.V balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: 1991656.00
DME.V balance_sheet (quarterly, 2025-06-30) — Other Equity Interest: 17501787.00
DME.V income_statement (quarterly, 2025-06-30) — Other Gand A: 204795.00
DME.V income_statement (quarterly, 2025-06-30) — Other Income Expense: -742.00
DME.V cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: -18925.00
DME.V balance_sheet (quarterly, 2025-06-30) — Other Non Current Assets: 799794.00
DME.V income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 134064.00
DME.V balance_sheet (quarterly, 2025-06-30) — Other Properties: 58116116.00
DME.V balance_sheet (quarterly, 2025-06-30) — Other Receivables: 130960.00
DME.V balance_sheet (quarterly, 2025-06-30) — Payables: 322840.00
DME.V balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 322840.00
DME.V balance_sheet (quarterly, 2025-06-30) — Prepaid Assets: 80622.00
DME.V income_statement (quarterly, 2025-06-30) — Pretax Income: -453168.00
DME.V balance_sheet (quarterly, 2025-06-30) — Receivables: 187462.00
DME.V income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 88006.00
DME.V income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 11936.00
DME.V balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -54394630.00
DME.V income_statement (quarterly, 2025-06-30) — Salaries And Wages: 16302.00
DME.V income_statement (quarterly, 2025-06-30) — Selling And Marketing Expense: 12747.00
DME.V income_statement (quarterly, 2025-06-30) — Selling General And Administration: 303734.00
DME.V balance_sheet (quarterly, 2025-06-30) — Share Issued: 94184109.00
DME.V income_statement (quarterly, 2025-06-30) — Special Income Charges: 0.00
DME.V cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 0.00
DME.V balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 46758212.00
DME.V balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 46758212.00
DME.V income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
DME.V income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.00
DME.V balance_sheet (quarterly, 2025-06-30) — Total Assets: 50060535.00
DME.V balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 46758212.00
DME.V balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 46758212.00
DME.V income_statement (quarterly, 2025-06-30) — Total Expenses: 619591.00
DME.V balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 3302323.00
DME.V balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 49416041.00
DME.V balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 2979483.00
DME.V income_statement (quarterly, 2025-06-30) — Total Unusual Items: -742.00
DME.V income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: -742.00
DME.V balance_sheet (quarterly, 2025-06-30) — Working Capital: 321654.00
DME.V income_statement (annual, 2025-09-30) — +Operating Expense: 2590508.00
DME.V income_statement (quarterly, 2025-09-30) — +Operating Expense: 697808.00
DME.V income_statement (annual, 2025-09-30) — +Total Revenue: 377228.00
DME.V income_statement (quarterly, 2025-09-30) — +Total Revenue: 15260.00
DME.V balance_sheet (annual, 2025-09-30) — Accounts Payable: 433266.00
DME.V balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 433266.00
DME.V balance_sheet (annual, 2025-09-30) — Accounts Receivable: 77868.00
DME.V balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 77868.00
DME.V balance_sheet (annual, 2025-09-30) — Accumulated Depreciation: -11180749.00
DME.V balance_sheet (quarterly, 2025-09-30) — Accumulated Depreciation: -11180749.00
DME.V income_statement (annual, 2025-09-30) — Basic Average Shares: 92363506.00
DME.V income_statement (annual, 2025-09-30) — Basic EPS: -0.02
DME.V cash_flow (annual, 2025-09-30) — Beginning Cash Position: 1183460.00
DME.V cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 376410.00
DME.V cash_flow (annual, 2025-09-30) — Capital Expenditure: -543250.00
DME.V cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -55219.00
DME.V cash_flow (annual, 2025-09-30) — Capital Expenditure Reported: -543250.00
DME.V cash_flow (quarterly, 2025-09-30) — Capital Expenditure Reported: -55219.00
DME.V balance_sheet (annual, 2025-09-30) — Capital Stock: 81562776.00
DME.V balance_sheet (quarterly, 2025-09-30) — Capital Stock: 81562776.00
DME.V balance_sheet (annual, 2025-09-30) — Cash And Cash Equivalents: 272542.00
DME.V balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 272542.00
DME.V balance_sheet (annual, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 272542.00
DME.V balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 272542.00
DME.V cash_flow (annual, 2025-09-30) — Cash Flow From Continuing Financing Activities: 887397.00
DME.V cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: -16143.00
DME.V cash_flow (annual, 2025-09-30) — Cash Flow From Continuing Investing Activities: 224932.00
DME.V cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: 257077.00
DME.V cash_flow (annual, 2025-09-30) — Cash Flow From Continuing Operating Activities: -2043057.00
DME.V cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: -467932.00
DME.V cash_flow (annual, 2025-09-30) — Change In Account Payable: 20353.00